Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS : A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects
This will be a Phase Ib, two-center study in approximately 160 healthy adults aged 18-55 yearsThe study is separated in two parts:Part A:The study starts with a single center open-label run-in phase of two dose levels (cohort 1 "low dose": 2x10^7 PFU, cohort 2 "high dose": 2x10^8 PFU) in 10 healthy subjects. 5 subjects will be allocated to each dose cohort and will receive immunization on day 0 and day 28.Part B:Two-center, randomized, double-blind, placebo-controlled, dose-finding study. This part is a double-blinded trial in approximately 150 healthy subjects. Subjects will be allocated to two different dose cohorts and a placebo cohort; each receiving three vaccine injections..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 11. Dez. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: October 8, 2019, Last downloaded: ClinicalTrials.gov processed this data on December 20, 2023, Last updated: December 20, 2023 |
---|
Study ID: |
NCT04119440 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003185338 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003185338 | ||
003 | DE-627 | ||
005 | 20231220010657.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003185338 | ||
035 | |a (UBBS_Klinische_Studien)NCT04119440 | ||
035 | |a (UBBS_Klinische_Studien)CEPI-MVA-MERS-S-Phase1b | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS |b A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: October 8, 2019, Last downloaded: ClinicalTrials.gov processed this data on December 20, 2023, Last updated: December 20, 2023 | ||
520 | |a This will be a Phase Ib, two-center study in approximately 160 healthy adults aged 18-55 yearsThe study is separated in two parts:Part A:The study starts with a single center open-label run-in phase of two dose levels (cohort 1 "low dose": 2x10^7 PFU, cohort 2 "high dose": 2x10^8 PFU) in 10 healthy subjects. 5 subjects will be allocated to each dose cohort and will receive immunization on day 0 and day 28.Part B:Two-center, randomized, double-blind, placebo-controlled, dose-finding study. This part is a double-blinded trial in approximately 150 healthy subjects. Subjects will be allocated to two different dose cohorts and a placebo cohort; each receiving three vaccine injections. | ||
650 | 2 | |a Coronavirus Infections | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Active, not recruiting | |
650 | 4 | |a Phase: Phase 1 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 11. Dez. |
773 | 1 | 8 | |g year:2023 |g day:11 |g month:12 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04119440 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 11 |c 12 |